Guangdong VTR Bio-Tech Co Ltd (300381) - Total Assets
Based on the latest financial reports, Guangdong VTR Bio-Tech Co Ltd (300381) holds total assets worth CN¥2.89 Billion CNY (≈ $423.60 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Guangdong VTR Bio-Tech Co Ltd (300381) shareholders funds for net asset value and shareholders' equity analysis.
Guangdong VTR Bio-Tech Co Ltd - Total Assets Trend (2007–2024)
This chart illustrates how Guangdong VTR Bio-Tech Co Ltd's total assets have evolved over time, based on quarterly financial data.
Guangdong VTR Bio-Tech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Guangdong VTR Bio-Tech Co Ltd's total assets of CN¥2.89 Billion consist of 43.5% current assets and 56.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.8% |
| Accounts Receivable | CN¥235.89 Million | 8.0% |
| Inventory | CN¥194.71 Million | 6.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥318.89 Million | 10.8% |
| Goodwill | CN¥36.67 Million | 1.2% |
Asset Composition Trend (2007–2024)
This chart illustrates how Guangdong VTR Bio-Tech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Guangdong VTR Bio-Tech Co Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guangdong VTR Bio-Tech Co Ltd's current assets represent 43.5% of total assets in 2024, a decrease from 55.7% in 2007.
- Cash Position: Cash and equivalents constituted 15.8% of total assets in 2024, up from 13.8% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 5.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 10.8% of total assets.
Guangdong VTR Bio-Tech Co Ltd Competitors by Total Assets
Key competitors of Guangdong VTR Bio-Tech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Guangdong VTR Bio-Tech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.56 | 5.78 | 1.82 |
| Quick Ratio | 4.61 | 5.03 | 0.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥966.20 Million | CN¥1.13 Billion | CN¥937.98 Million |
Guangdong VTR Bio-Tech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Guangdong VTR Bio-Tech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.31 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -4.7% |
| Total Assets | CN¥2.95 Billion |
| Market Capitalization | $497.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Guangdong VTR Bio-Tech Co Ltd's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Guangdong VTR Bio-Tech Co Ltd's assets decreased by 4.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Guangdong VTR Bio-Tech Co Ltd (2007–2024)
The table below shows the annual total assets of Guangdong VTR Bio-Tech Co Ltd from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.95 Billion ≈ $431.47 Million |
-4.73% |
| 2023-12-31 | CN¥3.09 Billion ≈ $452.89 Million |
-2.43% |
| 2022-12-31 | CN¥3.17 Billion ≈ $464.18 Million |
-29.19% |
| 2021-12-31 | CN¥4.48 Billion ≈ $655.56 Million |
-4.12% |
| 2020-12-31 | CN¥4.67 Billion ≈ $683.69 Million |
+3.41% |
| 2019-12-31 | CN¥4.52 Billion ≈ $661.14 Million |
-5.90% |
| 2018-12-31 | CN¥4.80 Billion ≈ $702.55 Million |
+24.86% |
| 2017-12-31 | CN¥3.85 Billion ≈ $562.68 Million |
+19.80% |
| 2016-12-31 | CN¥3.21 Billion ≈ $469.70 Million |
+30.89% |
| 2015-12-31 | CN¥2.45 Billion ≈ $358.84 Million |
+154.55% |
| 2014-12-31 | CN¥963.36 Million ≈ $140.97 Million |
+156.12% |
| 2013-12-31 | CN¥376.14 Million ≈ $55.04 Million |
+26.92% |
| 2012-12-31 | CN¥296.37 Million ≈ $43.37 Million |
+14.31% |
| 2011-12-31 | CN¥259.27 Million ≈ $37.94 Million |
+13.33% |
| 2010-12-31 | CN¥228.77 Million ≈ $33.48 Million |
+17.38% |
| 2009-12-31 | CN¥194.90 Million ≈ $28.52 Million |
+14.07% |
| 2008-12-31 | CN¥170.86 Million ≈ $25.00 Million |
+37.84% |
| 2007-12-31 | CN¥123.95 Million ≈ $18.14 Million |
-- |
About Guangdong VTR Bio-Tech Co Ltd
Guangdong VTR Bio-Tech Co., Ltd. researches, develops, produces, sells, and services bio-enzyme preparations, biosynthetics, and nutrition and health products in China and internationally. The company offers animal nutrition and health, biofuel, detergent, food and beverage, brewing, starch sweetness, bakery, plant extracts, pulp and paper, and textile enzymes, as well as biotechnology solutions.… Read more